Answers are grounded in this paper and cite their sources.
SUMMARY The use of recombinant activated factor VII (rFVIIa) in trauma patients is an exciting application because hemorrhage and coagulopathy play prominent roles both in the syndrome of severe hemorrhagic shock and in severe traumatic brain injury (TBI). Anecdotal use of rFVIIa in non‐hemophilic trauma patients extends back to 1999, and experience at individual institutions is now in the hundreds of cases. Efficacy in controlling traumatic coagulopathy approaches 80%, with long‐term survival of about half of the patients treated. There have been few reports of inappropriate thrombotic events in trauma patients. A single prospective randomized study of rFVIIa in victims of hemorrhagic shock has been completed, with some favorable results. Further trials in hemorrhagic shock are underway in both European and American trauma centers, while a trial in TBI patients will begin within the coming year.
No takes yet. Share an insight, caveat, or question.
Richard P. Dutton (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: